申请人:Zeneca Limited
公开号:US05367079A1
公开(公告)日:1994-11-22
The invention concerns cycloalkane derivatives of the formula I ##STR1## wherein Ar.sup.1 is phenyl, naphthyl or a 10-membered bicyclic heterocyclic moiety which may optionally bear up to four substituents; A.sup.1 is a direct link to X.sup.1 or is (1-3C)alkylene; X.sup.1 is oxy, thio, sulphinyl or sulphonyl; Ar.sup.2 is phenylene, pyridylene, pyrimidinylene, thiophenediyl, furandiyl, thiazolediyl or oxazolediyl which may optionally bear one or two substituents; p is 1 to 4; q is 0 to 2; R.sup.1 is hydrogen, (1-4C)alkyl, (2-4C)alkenyl or (3-4C)alkynyl; R.sup.2 is hydrogen, hydroxy, (1-4C)alkyl, (1-4C)alkoxy, (2-4C)alkenyloxy or (3-4C)alkynyloxy; or the OR.sup.1 and R.sup.2 groups together form a (1-4C)alkylenedioxy, oxo, thioxo, imino, hydroxyimino or (1-4C)alkoxyimino group; r is 0 to 3; and R.sup.3 is halogeno, trifluoromethyl or (1-4C)alkyl; or a pharmaceutically-acceptable salt thereof; processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.
该发明涉及公式I的环戊烷衍生物,其中Ar.sup.1是苯基、萘基或一个可选择携带最多四个取代基的10-成员双环杂环基;A.sup.1是直接连接到X.sup.1或是(1-3C)烷基;X.sup.1是氧、硫、亚硫酰基或磺酰基;Ar.sup.2是苯基、吡啶基、嘧啶基、噻吩二基、呋喃二基、噻唑二基或噁唑二基,可选择携带一个或两个取代基;p为1至4;q为0至2;R.sup.1是氢、(1-4C)烷基、(2-4C)烯基或(3-4C)炔基;R.sup.2是氢、羟基、(1-4C)烷基、(1-4C)烷氧基、(2-4C)烯氧基或(3-4C)炔氧基;或OR.sup.1和R.sup.2基共同形成(1-4C)烷基二氧、氧、硫氧、亚胺、羟亚胺或(1-4C)烷氧亚胺基团;r为0至3;R.sup.3是卤、三氟甲基或(1-4C)烷基;或其药用接受的盐;其制备方法;含有它们的药物组合物以及它们作为5-脂氧合酶抑制剂的用途。